Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 July 2024
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 21 May 2025
Delgocitinib for treating moderate to severe chronic hand eczema ID6408Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC